Schering-Plough’s R&D Spending Surges Ahead Of Sales Gains
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm’s large number of Phase III products are an expensive opportunity.
You may also be interested in...
Novacea, Schering-Plough Ink Deal To Develop, Commercialize Cancer Drug Asentar
Novacea emphasizes collaborative nature of the agreement, pointing to pre-commercial milestones and larger-than-usual royalties on sales.
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
Hassan discusses Schering’s late-stage pipeline, including the protease inhibitor boceprevir for hepatitis C and SCH 530348, a thrombin receptor agonist intended as an add-on to Plavix therapy.
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Hassan discusses changes in the industry, the importance of emerging markets such as Asia, the debate over follow-on biologics and the PDUFA reauthorization.